Clinical trial
PCSK9 Inhibition After Heart Transplantation
NCT03537742 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- PCSK9 Inhibition After Heart Transplantation
- Lead sponsor
- Stanford University
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 13, 2019
- Completion date
- July 11, 2025
- Enrollment
- 114 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
vasculopathy